JASMY Price Jumps 83% as Bulls Target $0.00783 Next
- JASMY gained 83% from Crypto Patel’s earlier accumulation zone.
- A weekly move above $0.00783 could strengthen the bullish reversal.
- Immediate resistance sits near $0.00580 to $0.00600 before higher targets.
The JASMY price traded near $0.00547 after gaining 1.48%, following a sharp move toward $0.00620. The token has recovered significantly from its mid-September low near $0.00360. Analysts now see signs of a larger reversal after an extended downtrend. However, several resistance levels still stand between JASMY and its longer-term bullish targets.
JASMY Price Holds Support as Weekly Reversal Setup Develops
Crypto Patel said the JASMY price has risen about 83% from his $0.0044 to $0.0032 accumulation zone. He highlighted a weekly falling-channel structure that has held support.
The analyst identified $0.00783 as the main level needed for a bullish macro shift. His longer-term targets stand at $0.020, $0.050 and $0.15.
Patel compared the setup with an earlier structure that preceded a roughly 1,900% rally. However, he listed $0.00273 as the weekly closing invalidation level.
Vuori Trading also maintains a longer-term target range between $0.12 and $0.23. That outlook depends on the underlying support structure remaining intact.
JASMY Price Consolidates After Sharp Four-Hour Recovery
On the four-hour timeframe, the JASMY price has pulled back after reaching a local high near $0.00620. It currently remains above the important $0.00500 support area.
RSI stands at 54.06, showing neutral momentum after cooling from readings near 70. Immediate resistance sits between $0.00580 and $0.00600.
A breakout above $0.00600 could push the JASMY price toward $0.00650. That move would bring the larger $0.00783 breakout level closer.
Meanwhile, support sits near $0.00520, followed by $0.00500. Losing $0.00500 could expose a deeper retracement toward $0.00450.
The technical structure therefore leaves JASMY between short-term consolidation and a potential larger weekly reversal.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - RBC expects gradual improvement in North American and European building materials stocks in the third quarter
October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)
3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million
Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.
Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.
Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.
Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.
Crypto prices
More
